X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.09+0.26 (+9.19%)
Close on Nov 17, 2026Market cap $306.36MP/E –Yield –
X4 Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
X4 Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$76.10M. For fiscal 2025 it was -$85.62M. The highest annual figure on record is -$21.31M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$85.62M | – |
| FY2024 | Dec 31, 2024 | -$130.90M | – |
| FY2023 | Dec 31, 2023 | -$96.51M | – |
| FY2022 | Dec 31, 2022 | -$77.10M | – |
| FY2021 | Dec 31, 2021 | -$70.91M | – |
| FY2020 | Dec 31, 2020 | -$58.82M | – |
| FY2019 | Dec 31, 2019 | -$48.06M | – |
| FY2018 | Dec 31, 2018 | -$25.42M | – |
| FY2017 | Dec 31, 2017 | -$21.31M | – |
| FY2016 | Dec 31, 2016 | -$21.64M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.19M | – |
| Q2 FY2026 | Jun 30, 2026 | -$20.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.03M | – |
| Q2 FY2024 | Jun 30, 2024 | -$63.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.60M | – |
| Q2 FY2023 | Jun 30, 2023 | -$47.90M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.09M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.31M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.44M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.50M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.33M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.46M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.53M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.24M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.77M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.29M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.75M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.73M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.72M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.78M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.18M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.35M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.09M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.36M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.51M | – |
See a number that looks wrong?